Kazuya Sugimori

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda et al. · Journal of Clinical Oncology · 2013 · 624 citations

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Chigusa Morizane, Takuji Okusaka, Junki Mizusawa et al. · Annals of Oncology · 2019 · 320 citations

S-1 Versus Gemcitabine, Gastrointestinal Oncology, Medicine +7

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

Kohei Nakachi, Masafumi Ikeda, Masaru Konishi et al. · The Lancet · 2023 · 214 citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +9

Treatment of hepatocellular carcinoma with radiofrequency ablation: Radiologic-histologic correlation during follow-up periods

Manabu Morimoto, Kazuya Sugimori, Kazuhito Shirato et al. · Hepatology · 2002 · 155 citations · Full text

Surgical Oncology, Pathology, Interventional Radiology +18

Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms

Ryonho Koh, Kingo Hirasawa, Sei Yahara et al. · Gastrointestinal Endoscopy · 2013 · 128 citations

Antithrombotic Drugs, Gastroenterology, Eus-guided Gastroenterostomy +6